Recombinant ErbB2/Her2 (Pertuzumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Recombinant Antibody
-
- Target See all ErbB2/Her2 (Pertuzumab Biosimilar) products
- ErbB2/Her2 (Pertuzumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This ErbB2/Her2 (Pertuzumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Pertuzumab Biosimilar, Human HER2 Monoclonal Antibody
- Specificity
- The monoclonal antibody pertuzumab biosimilar specifically binds to the human HER2/ErbB-2/c-neu.
- Characteristics
- Recombinant humanized IgG1 Monoclonal Antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The monoclonal antibody pertuzumab biosimilar was produced in the pertuzumab biosimilar CHO stable cell line.
- Isotype
- IgG1 kappa
-
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- ErbB2/Her2 (Pertuzumab Biosimilar)
- Abstract
- ErbB2/Her2 (Pertuzumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.
-
You are here:
